Status:
RECRUITING
Alpha-Synuclein PET/CT in Various α-Syn-Related Disease
Lead Sponsor:
Tianjin Medical University
Collaborating Sponsors:
Tianjin Medical University General Hospital
Conditions:
Alpha Synuclein Pathology
Alpha-Synuclein
Eligibility:
All Genders
18-80 years
Brief Summary
To evaluate the potential usefulness of 18F-FIAT-2, 18F-C05-05, 18F-SPAL-T-06 positron emission tomography/computed tomography (PET/CT) for the diagnosis of primary and metastatic lesions in various α...
Detailed Description
Subjects with various α-Syn-related disease patients underwent 18F-FIAT-2, 18F-C05-05, 18F-SPAL-T-06 PET/CT either for an initial assessment or for recurrence detection. Lesions uptake was quantified...
Eligibility Criteria
Inclusion
- (i) adult patients (aged 18 years or order); (ii) patients with suspected or new diagnosed or previously treated PD (supporting evidence may include MRI, CT, tumor markers and pathology report); (iii) patients who had scheduled α-Syn PET/CT scan; (iv) patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee.
Exclusion
- (i) patients with none PD syndrome; (ii) patients with pregnancy; (iii) the inability or unwillingness of the research participant, parent or legal representative to provide written informed consent.
Key Trial Info
Start Date :
April 1 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
April 1 2028
Estimated Enrollment :
500 Patients enrolled
Trial Details
Trial ID
NCT06949670
Start Date
April 1 2025
End Date
April 1 2028
Last Update
April 29 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Tianjin Medical University General Hospital
Tianjin, Tianjin Municipality, China, 300052